home / stock / hgen / hgen news

HGEN News and Press, Humanigen Inc. From 06/03/19

Stock Information
Company Name: Humanigen Inc.
Stock Symbol: HGEN
Market: OTC
Website: humanigen.com
Menu
HGEN HGEN Quote HGEN Short HGEN News HGEN Articles HGEN Message Board
Get HGEN Alerts

News, Short Squeeze, Breakout and More Instantly...
HGEN - Humanigen to Present at the Jefferies 2019 Healthcare Conference

BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered ® monoclonal antibodies focused on chimeric antigen receptor T (CAR-T) cell therapy optimiza...
HGEN - Gilead teams up with Humanigen in study of combo therapy for DLBCL

Gilead Sciences ( GILD -1.7% ) unit Kite Pharma will collaborate with Humanigen ( OTCQB:HGEN +8.7% ) on a Phase 1/2 clinical trial evaluating the combination of CAR T therapy Yescarta (axicabtagene ciloleucel) and lenzilumab in patients with relapsed/refractory diffuse large B-cell lym...

HGEN - Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

SANTA MONICA, Calif. and BURLINGAME, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Kite, a Gilead Company (Nasdaq: GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal ant...

HGEN - Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclon...
HGEN - Publication in blood® Highlights Potential for GM-CSF Neutralization as a Solution for CAR-T Induced Neurotoxicity

Severe neurotoxicity (NT) is a negative prognostic factor for overall survival with chimeric antigen receptor T-cell (CAR-T) therapy Prolonged exposure of corticosteroids for severe NT may negatively in fl uence overall survival GM-CSF neutralization identified as a pote...

HGEN - Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Study Demonstrates that Dosing with Ifabotuzumab Results in Rapid, Specific and Reproducible Targeting of the Tumor Microenvironment in Patients with Glioblastoma Multiforme (GBM) Imaging Changes Suggest Modulation of the Tumor Vasculature by Ifabotuzumab without Normal Tissue ...

HGEN - Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy

Enhanced anti-tumor activity, improved overall survival, and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization Lenzilumab (an anti-GM-CSF monoclonal antibody) used in combination with CAR-T therapy prevents cytokine release syndrome,...
HGEN - Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting

First ever demonstration that the spectrum of toxicities seen in CAR-T clinical trials can be effectively prevented in vivo Enhanced anti-tumor activity, improved overall survival, and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralizatio...

HGEN - Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of 'blood'®, The Official Journal of the American Society of Hematology (ASH)

Enhanced anti-tumor activity, improved overall survival, and an exponential increase in CAR-T cell proliferation was observed with GM-CSF neutralization Lenzilumab (an anti-GM-CSF antibody) used in combination with CAR-T significantly reduces neuro-inflammation, prevents cytokine r...

Previous 10 Next 10